Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Summary

The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Obesity
• Overweight

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 99 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Amgen

Last updated on ClinicalTrials.gov

October 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites